Randomized Things News
WEDNESDAY, Sept. 1 (HealthDay News) -- A drug widely used to treat high blood sugar in type 2 diabetics may hold some promise in the prevention of tobacco-induced lung cancer, according to extremely preliminary findings in a mouse study.Is sodium the new villain? Politicians and food companies race to reduce salt.We've had our first hands-on time with Black Ops, the Cold War-spanning opus that finds Treyarch mining new eras for face-blasting inspiration.According to remarks from David Vondehaar of Treyarch, Call of Duty: Black Ops will ship with about 14 maps on the disc when the game hits on November 9th. I had the chance to try out some of the various new multiplayer maps and match types last night and came away impressed. (More on Techland: [...]The Swiss health authority Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new therapeutic option for newly diagnosed patients since the introduction of Glivec® (imatinib), providing a major advance for ...Taking a dietary supplement of organic zinc and the enzyme phytase four days before receiving botulinium toxin injections made the toxin more effective in 93 percent of patients tested in a recent study at The Methodist Hospital in Houston.The surgical removal of ovaries or breasts significantly improves the longevity of women who are most at risk for breast and ovarian cancer, according to a study published Tuesday in the Journal of the American Medical Association (JAMA). Researchers observed nearly 2,500 carriers of the BRCA1 and BRCA2 gene mutations in the United States, England, [...]COLUMBIA, Md. , Sept. 1 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK - News ) today announced its financial results for the third quarter of fiscal 2010. Revenues for the third quarter were $117.2 million , up 51% from $77.8 million in the third quarter of fiscal 2009. GAAP net income was $11.9 million , or $0.35 per diluted share, for the third quarter of fiscal 2010 ...Welcome to the real life world of comparative effectiveness research, that politically and pundit-popular means to decide which treatment approach doctors should utilize and which, based on the results of these studies, our government will decide which approach they will fund.Allergan Inc. Posted on:01 Sep 10 Allergan, Inc. (NYSE: AGN) today announced that it has reached a resolution with the United States Department of Justice (DOJ) regarding the previously reported Government investigation into Allergan's past U.S. sales and marketing practices relating to certain therapeutic uses of BOTOX® (onabotulinumtoxinA).Yahoo! News Search Results for Randomized Things
